David McIntyre
CIK: 0001404254
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)2 (100.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
IKT
Inhibikase Therapeutics, Inc.
Officer
Discretionary Trading P&L
Holdings
About McIntyre David
McIntyre David (SEC CIK 0001404254) files insider reports with the SEC as Chief Financial Officer of Inhibikase Therapeutics, Inc. (IKT).
Signal8 holds 3 ownership filings by McIntyre David (1 Form 3, 2 Form 4), filed between Apr 16, 2025 and Jan 7, 2026. Those filings report 2 transactions, from Apr 14, 2025 to Jan 5, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on McIntyre David's filings is in WILMINGTON, DE.
Recent filings by McIntyre David
Other insiders filing for Inhibikase Therapeutics, Inc. (IKT)
- Wasserman Scott M., Director
- RA CAPITAL MANAGEMENT, L.P., 10% Owner
- Aurentz Vincent, Director
- Cabell Christopher, President & Head of R&D
- Munshi Amit, Director
- Iwicki Mark T, Chief Executive Officer